Ovoca Bio (DUB:OVXA) Receivables Turnover : 0.00 (As of Jun. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Ovoca Bio Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Ovoca Bio's Revenue for the six months ended in Jun. 2023 was €0.00 Mil. Ovoca Bio's average Accounts Receivable for the six months ended in Jun. 2023 was €0.21 Mil.

Ovoca Bio Receivables Turnover Historical Data

The historical data trend for Ovoca Bio's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ovoca Bio Receivables Turnover Chart

Ovoca Bio Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Receivables Turnover

Get a 7-Day Free Trial

Ovoca Bio Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Receivables Turnover	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Ovoca Bio's Receivables Turnover

For the Biotechnology subindustry, Ovoca Bio's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ovoca Bio's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ovoca Bio's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Ovoca Bio's Receivables Turnover falls into.

Ovoca Bio Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Ovoca Bio's Receivables Turnover for the fiscal year that ended in Dec. 2022 is calculated as

	Receivables Turnover (A: Dec. 2022 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Dec. 2022 )	/ (	(Accounts Receivable (A: Dec. 2021 )	+	Accounts Receivable (A: Dec. 2022 ))	/	count )
=	0	/ (	(0	+	0)	/	1 )
=	0	/	0
=	N/A

Ovoca Bio's Receivables Turnover for the quarter that ended in Jun. 2023 is calculated as

	Receivables Turnover (Q: Jun. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Jun. 2023 )	/ (	(Accounts Receivable (Q: Dec. 2022 )	+	Accounts Receivable (Q: Jun. 2023 ))	/	count )
=	0	/ (	(0	+	0.211)	/	1 )
=	0	/	0.211
=	N/A

Ovoca Bio (DUB:OVXA) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Ovoca Bio Receivables Turnover Related Terms

Thank you for viewing the detailed overview of Ovoca Bio's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Ovoca Bio (DUB:OVXA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ovoca Bio PLC (DUB:OVXA) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

OVB.GB:UK OVB:UK OVXA:Germany

Address

17 Pembroke Street Upper, Dublin, IRL, D02 AT22

Website

https://www.ovocabio.com

Ovoca Bio PLC is a life science investment company. The company is engaged in investing in the development and commercialization of novel product candidates for the treatment of female sexual dysfunctions. The group has two business segments, bio-pharmaceutical and investment, which are operated principally in Russian Federation and investment activities operated from Bermuda, and with administrative activities in the Republic of Ireland. Its product candidate includes IVIX - Libicore - a novel synthetic peptide, administrated through a nasal spray.

Ovoca Bio (DUB:OVXA) Headlines

No Headlines